HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced today that it has entered into an underwriting agreement relating to the sale of 3,750,000 shares of its common stock at $18.50 per share, pursuant to Acorda’s previously filed registration statement, which was declared effective by the Securities and Exchange Commission on June 7, 2007. Of the shares being sold, 3,626,960 shares are being sold by the Company and 123,040 shares are being sold by certain affiliate stockholders. Acorda Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of common stock at the public offering price.
